Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
SANTA MONICA, Calif., Feb. 24, 2016 -- Kite Pharma, Inc., (Nasdaq:KITE) today announced that it will report fourth quarter and full year 2015 financial results on Monday, February 29, 2016 after market close, and will host a conference call to discuss financial results and provide a business update at 4:30 PM Eastern Time (1:30 PM Pacific Time).
Audio Webcast
Interested parties may access a live audio webcast of the conference call on the Investors section of Kite’s website, www.kitepharma.com. A replay of the webcast will be available on the website for approximately 30 days.
Dial-In Information
Live (U.S. / Canada): (877) 301-8565
Live (International): (678) 562-4240
Confirmation number: 45173015
About Kite Pharma
Kite Pharma, Inc., is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on engineered autologous cell therapy (eACT™) designed to restore the immune system's ability to recognize and eradicate tumors. Kite is based in Santa Monica, CA. For more information on Kite Pharma, please visit www.kitepharma.com. Sign up to follow @KitePharma on Twitter at www.twitter.com/kitepharma.
CONTACT: Greg Mann VP, Investor Relations [email protected] For Media: Justin Jackson Burns McClellan (212) 213-0006 [email protected]
